SNMMI, the Mayo Clinic, Washington University School of Medicine in St. Louis, and Memorial Sloan Kettering Cancer Center have jointly filed comments with the U.S. Food and Drug Administration (FDA) with recommendations that would make it easier for patients with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs) to tolerate and, therefore, benefit from lutetium-177 (¹⁷⁷Lu) DOTATATE therapy. {read more here}